ESTRO 2025 - Abstract Book

S239

Brachytherapy - Gynaecology

ESTRO 2025

Conclusion: Brachytherapy using Hybrid Geneva Applicator with needle loading and optimization offers superiority in terms of target dose coverage and better OAR sparing in patients of locally advanced cervical cancer, following CTRT. Long term follow-up could assess outcomes and dosimetry advantages translating into clinical improvement using this applicator.

Keywords: Cancer Cervix, Brachytherapy, Geneva applicator

1844

Digital Poster Dosimetric comparison of brachytherapy and MRLinac boost for locally advanced cervical cancer Renske van Noortwijk, Petra Kroon, Katelijne van Vliet - van den Ende, Jochem Hes, Gonda Sikkes, Alexis Kotte, Erik Brondijk, Ina Jürgenliemk-Schulz, Femke van der Leij, Astrid van Lier Department of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands Purpose/Objective: Currently, patients with locally advanced cervical cancer (LACC) are treated with a brachytherapy (BT) boost after chemoradiation [1]. In rare cases, BT is not possible and a MRLinac (MRL) boost might be an alternative. To investigate the potential dosimetric penalty of performing an MRL treatment instead of a BT treatment, we compared dose distributions and anatomical differences of both treatments. Material/Methods: Two groups of ten patients treated with BT boost were selected from our clinical database. In group 1, ≥1 of the target constraints was not achieved in the BT treatment plans; in group 2 all target constraints were achieved. Our